Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 824

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Open access
Diener, Hans-Christoph, Sacco, Ralph L., Easton, J. Donald, Granger, Christopher B., Bernstein, Richard A., Uchiyama, Shinichiro, Kreuzer, Jörg, Cronin, Lisa, Cotton, Daniel, Grauer, Claudia, Brueckmann, Martina, Chernyatina, Marina, Donnan, Geoffrey, Ferro, José M., Grond, Martin, Kallmünzer, Bernd, Krupinski, Jerzy, Lee, Byung-Chul, Lemmens, Robin, Masjuan, Jaime, Odinak, Miroslav, Saver, Jeffrey L., Schellinger, Peter D., Toni, Danilo, Toyoda, Kazunori·2019·New England Journal of Medicine

Abstract

BACKGROUND: Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear. METHODS: We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source. The primary outcome was recurrent stroke. The primary safety outcome was major bleeding. RESULTS: A total of 5390 patients were enrolled at 564 sites and were randomly assigned to receive dabigatran (2695 patients) or aspirin (2695 patients). During a median follow-up of 19 months, recurrent strokes occurred in 177 patients (6.6%) in the dabigatran group (4.1% per year) and in 207 patients (7.7%) in the aspirin group (4.8% per year) (hazard ratio, 0.85; 95% confidence interval [CI], 0.69 to 1.03; P = 0.10). Ischemic strokes occurred in 172 patients (4.0% per year) and 203 patients (4.7% per year), respectively (hazard ratio, 0.84; 95% CI, 0.68 to 1.03). Major bleeding occurred in 77 patients (1.7% per year) in the dabigatran group and in 64 patients (1.4% per year) in the aspirin group (hazard ratio, 1.19; 95% CI, 0.85 to 1.66). Clinically relevant nonmajor bleeding occurred in 70 patients (1.6% per year) and 41 patients (0.9% per year), respectively. CONCLUSIONS: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke. The incidence of major bleeding was not greater in the dabigatran group than in the aspirin group, but there were more clinically relevant nonmajor bleeding events in the dabigatran group. (Funded by Boehringer Ingelheim; RE-SPECT ESUS ClinicalTrials.gov number, NCT02239120.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1813959

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 824

Metadata

Authors
Diener, H.-C., Sacco, R. L., Easton, J. D., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., Brueckmann, M., Chernyatina, M., Donnan, G., Ferro, J. M., Grond, M., Kallmünzer, B., Krupinski, J., Lee, B.-C., Lemmens, R., Masjuan, J., Odinak, M., Saver, J. L., Schellinger, P. D., Toni, D., & Toyoda, K.
Venue
New England Journal of Medicine
Published
2019-05-16
Volume
380
Issue
20
Pages
1906-1917
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2945825099
Cited by
824
References
15
FWCI
77.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. https://app.cochat.ai/papers/10.1056/nejmoa1813959
The paper
Diener, H.-C., Sacco, R. L., Easton, J. D., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., Brueckmann, M., Chernyatina, M., Donnan, G., Ferro, J. M., Grond, M., Kallmünzer, B., Krupinski, J., Lee, B.-C., Lemmens, R., . . . Toyoda, K. (2019). Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1813959

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.